We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-7.99%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.84B
AUM Growth
-$861M
Cap. Flow
-$303M
Cap. Flow %
-7.88%
Top 10 Hldgs %
67.4%
Holding
122
New
18
Increased
22
Reduced
23
Closed
17

Top Buys

Rank Stock Value
1
RUBY
Rubius Therapeutics, Inc
RUBY
+$66.5M
2
FOLD
Amicus Therapeutics
FOLD
+$15.4M
3
NIO icon
NIO
NIO
+$12.4M
4
BABA icon
Alibaba
BABA
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$8.3M

Top Sells

Rank Stock Value
1
WW
WW International
WW
+$487M
2
BPMC
Blueprint Medicines
BPMC
+$13.9M
3
ONC
BeOne Medicines Ltd
ONC
+$12.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.04M
5
IMUX icon
Immunic
IMUX
+$6.85M

Sector Composition

Rank Sector Weight
1 Healthcare 45.68%
2 Consumer Discretionary 28.3%
3 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BABA icon
51
Alibaba
BABA
$293B
$10.7M 0.28%
+65,000
New +$11.5M
MDGL icon
52
Madrigal Pharmaceuticals
MDGL
$11.7B
$10.7M 0.28%
50,000
– –
SLDB icon
53
Solid Biosciences
SLDB
$974M
$10.6M 0.28%
15,000
-1,667
-10% -$1.05M
NIO icon
54
NIO
NIO
$11.3B
$10.5M 0.27%
+1,500,000
New +$12.4M
BOLD
55
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.9M 0.26%
250,000
+14,000
+6% +$522K
RCKT icon
56
Rocket Pharmaceuticals
RCKT
$367M
$9.85M 0.26%
400,000
– –
LRMR icon
57
Larimar Therapeutics
LRMR
$444M
$9.35M 0.24%
66,667
-33,333
-33% -$4.05M
CBAY
58
DELISTED
Cymabay Therapeutics
CBAY
$8.86M 0.23%
800,000
– –
ALNY icon
59
CALL
Alnylam Pharmaceuticals
ALNY
$30.4B
$8.75M 0.23%
100,000
– –
RNAC icon
60
Cartesian Therapeutics
RNAC
$264M
$8.73M 0.23%
18,718
+2,051
+12% +$824K
IOVA icon
61
Iovance Biotherapeutics
IOVA
$2.95B
$7.88M 0.2%
700,000
– –
CMTA
62
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$7.72M 0.2%
692,000
+492,000
+246% +$5.18M
ACET icon
63
Adicet Bio
ACET
$77.3M
$7.57M 0.2%
4,464
-447
-9% -$583K
REPL icon
64
Replimune Group
REPL
$1.42B
$7.25M 0.19%
+450,000
New +$7.89M
STML
65
DELISTED
Stemline Therapeutics, Inc.
STML
$6.64M 0.17%
400,000
– –
DRNA
66
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$6.49M 0.17%
425,000
– –
SPRO icon
67
Spero Therapeutics
SPRO
$71.8M
$6.31M 0.16%
600,000
+250,000
+71% +$2.9M
YI
68
111 Inc
YI
$33.4M
$6.08M 0.16%
+45,000
New +$6.29M
ACIU icon
69
AC Immune
ACIU
$262M
$6M 0.16%
750,000
+150,000
+25% +$1.51M
TBIO
70
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$6M 0.16%
600,000
+100,000
+20% +$1.16M
AGEN
71
Agenus
AGEN
$315M
$5.88M 0.15%
140,113
– –
LOGM
72
DELISTED
LogMein, Inc.
LOGM
$5.79M 0.15%
+65,000
New +$5.88M
CRNX icon
73
Crinetics Pharmaceuticals
CRNX
$8.96B
$5.73M 0.15%
+200,000
New +$5.94M
TECX
74
Tectonic Therapeutic
TECX
$664M
$5.19M 0.13%
8,333
-2,084
-20% -$924K
SGMO
75
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.08M 0.13%
300,000
+100,000
+50% +$1.52M
1 2
3
4 5

Similar funds

GP
Greenline Partners New York $930M AUM 29.59% 1-Year Est. Return
BCC
Biglari Capital Corp San Antonio, Texas $929M AUM 39.8% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
ICM
Innovator Capital Management Wheaton, Illinois $925M AUM 49.11% 1-Year Est. Return
OCM
OLP Capital Management Causeway Bay, Hong Kong $942M AUM 5.25% 1-Year Est. Return

Artal Group's Q3 2018 Portfolio in Review

As of Q3 2018, Artal Group held 122 positions worth $3.84B, down 18% from $4.71B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Artal Group withdrew a net $303M in Q3 2018, closing 17 positions and reducing 23 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $9.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 36% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Artal Group opened a new position in Rubius Therapeutics, Inc worth $69.8M.

  • Artal Group's largest Q3 2018 buy was Rubius Therapeutics, Inc: 2,908,791 shares worth $69.8M.
  • Artal Group added most to Amicus Therapeutics in Q3 2018, an estimated $15.4M increase.
  • Artal Group's biggest Q3 2018 reduction was WW International, cutting an estimated $487M.
  • Artal Group fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $9.04M.
  • Artal Group's ten largest holdings make up 67% of its $3.84B portfolio in Q3 2018.
  • Artal Group opened 18 new positions and closed 17 in Q3 2018.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.84B.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.